ホーム › 卵巣がん › カリフォルニア州 › San Diego
San Diego、CAにおける卵巣がんの臨床試験
San Diegoとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- UC San Diego Medical Center - Hillcrest, San Diego
- Sharp Memorial Hospital, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11マイル先
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of San Diego Moores Cancer Center, La Jolla · 11マイル先
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891, San Diego
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- University of California San Diego, La Jolla · 11マイル先
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Moores Cancer Center, La Jolla · 11マイル先
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- UC San Diego Health - Moores Cancer Center /ID# 277574, La Jolla · 11マイル先
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- University of California, San Diego-Moores Cancer Center, La Jolla · 11マイル先
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第2相
- Scripps Healthscripps Mercy Hospital Prebys Cancer Center, San Diego
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- University of California, San Diego, La Jolla · 11マイル先
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
被験者募集中第2相
- UC San Diego Health, La Jolla · 11マイル先
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Scripps Health, San Diego
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11マイル先
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
被験者募集中第1相
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
被験者募集中第3相
- UC San Diego Health - Moores Cancer Center, La Jolla · 11マイル先
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11マイル先
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- University of California, San Diego; Moores Cancer Center, San Diego
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #101, La Jolla · 11マイル先
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
被験者募集中第3相
- Scripps Clinic, La Jolla · 11マイル先
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- UCSD Moores Cancer Center, La Jolla · 11マイル先
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
被験者募集中第3相
- University of California San Diego Moores Cancer Center, La Jolla · 11マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, La Jolla · 11マイル先
A Beta-only IL-2 ImmunoTherapY Study
被験者募集中第1/2相
- Sharp Memorial Hospital, San Diego
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
San Diegoにおける他の研究
- 非小細胞肺癌48件の研究
- 乳がん41件の研究
- がん（全種類）32件の研究
- 前立腺がん31件の研究
- 転移性癌30件の研究
- 大腸癌25件の研究
- 膵臓がん24件の研究
- 肺がん23件の研究
- 肥満症23件の研究
- 心不全23件の研究
- うつ病21件の研究
- 悪性黒色腫18件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。